



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Mundy *et al.* Art Unit : 1644  
Serial No. : 10/086,217 Examiner : Maher M. Haddad  
Filed : February 21, 2002  
Title : METHODS OF TREATING MULTIPLE MYELOMA AND MYELOMA-  
INDUCED BONE RESORPTION USING INTEGRIN ANTAGONISTS

**MAIL STOP RCE**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form. Under 37 C.F.R. § 1.98 (a)(2)(ii), only copies of foreign patent documents and/or non-patent literature are enclosed. Copies of any listed U.S. patents or U.S. patent application publications can be provided upon request.

Applicants wish to bring to the Examiner's attention the following co-pending U.S. applications:

- 09/805,840; filed March 13, 2001
- 10/095,496; filed March 12, 2002
- 10/170,841; filed June 13, 2002
- 11/215,257; filed August 29, 2005
- 10/234,041; filed September 3, 2002
- 11/169,171; filed June 28, 2005
- 10/252,978; filed September 23, 2002
- 10/428,662; filed May 2, 2003
- 11/103,362; filed April 11, 2005

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

September 11, 2006  
Date of Deposit

[Signature]  
Signature

[Typed Name]  
Typed or Printed Name of Person Signing Certificate

Applicant : Mundy *et al.*  
Serial No. : 10/086,217  
Filed : February 21, 2002  
Page : 2 of 2

Attorney's Docket No.: 10274-063001 / A061 US 004

This statement is being filed after a final Office Action, but before payment of the issue fee.


A check for \$180 in payment of the late submission fee of § 1.17(p) is enclosed. Please apply any other charges or credits to Deposit Account No. 06-1050, referencing Attorney's Docket Number 10274-063001.

Respectfully submitted,

Date: September 11, 2006

Allyson R. Hatton  
Allyson R. Hatton, Ph.D.  
Reg. No. 54,154

Fish & Richardson P.C.  
225 Franklin Street  
Boston, MA 02110  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10274-063001	Application No. 10/086,217
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant <b>Mundy <i>et al.</i></b>	
		Filing Date February 21, 2002	Group Art Unit 1644

### U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	BA	5,217,870	06/08/1993	Hession <i>et al.</i>			
	BB	5,272,263	12/21/1993	Hession <i>et al.</i>			
	BC	5,367,056	11/22/1994	Hession <i>et al.</i>			
	BD	5,695,755	12/09/1997	Papayannopoulou			
	BE	5,824,304	10/20/1998	Papayannopoulou			
	BF	5,843,438	12/01/1998	Papayannopoulou			
	BG	5,871,734	02/16/1999	Lobb <i>et al.</i>			
	BH	5,888,507	03/30/1999	Burkly			
	BI	5,932,214	08/03/1999	Lobb <i>et al.</i>			
	BJ	6,252,043	06/26/2001	Hession <i>et al.</i>			
	BK	6,307,025	10/23/2001	Hession <i>et al.</i>			
	BL	6,602,503	08/05/2003	Lobb <i>et al.</i>			
	BM						

### Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	BN	WO 90/13300	11/15/1990	WIPO				
	BO	WO 93/13798	07/22/1993	WIPO				
	BP	WO 93/15764	08/19/1993	WIPO				
	BQ	WO 94/11027	05/26/1994	WIPO				
	BR	WO 94/16094	07/21/1994	WIPO				
	BS	WO 94/17828	08/18/1994	WIPO				
	BT							

### Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	BU	Chevalier <i>et al.</i> , "Interleukin-6 Family of Cytokines Induced Activation of Different Functional Sites Expressed by gp130 Transducing Protein," <i>J. Biol. Chem.</i> 271:14764-14772, 1996.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10274-063001	Application No. 10/086,217
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Mundy <i>et al.</i>	
		Filing Date February 21, 2002	Group Art Unit 1644

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	BV	Hemler <i>et al.</i> , "Characterization of the Cell Surface Heterodimer VLA-4 and Related Peptides," <i>J. Biol. Chem.</i> 262:11478-11485, 1987.
	BW	Mori <i>et al.</i> , "Anti- $\alpha$ 4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis," <i>Blood</i> 104:2149-2154, 2004.
	BX	Pulido <i>et al.</i> , "Functional Evidence for Three Distinct and Independently Inhibitable Adhesion Activities Mediated by the Human Integrin VLA-4," <i>J. Biol. Chem.</i> 266:10241-10245, 1991.
	BY	Sanchez-Madrid <i>et al.</i> , "VLA-3: A novel polypeptide association within the VLA molecular complex: cell distribution and biochemical characterization," <i>Eur. J. Immunol.</i> 16:1343-1349, 1986.
	BZ	Schwabe <i>et al.</i> , "Differential Expression and Ligand-induced Modulation of the Human Interleukin-6 Receptor on Interleukin-6-responsive Cells," <i>J. Biol. Chem.</i> 269:7201-7209, 1994.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	